In a long-term follow-up study of a multicenter, sham-controlled trial, eyes of patients with retinitis pigmentosa treated with CNTF (delivered via an intraocular encapsulated cell implant) exhibited greater loss of total visual field sensitivity compared to sham-treated eyes. This evidence concerns the gene CNTF and retinitis pigmentosa.